fls.txt
The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.


item1.txt
 The FASB defines the fair value of financial instruments as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
This update provides guidance on how to record eight specific cash flow issues.
The Company is currently evaluating the effect of this update on its consolidated financial statements.
 See notes to unaudited condensed consolidated financial statements.
For the six months ended December 31, 2017 and 2016, respectively, two customers accounted in the aggregate for approximately 11% and 16% of net sales of the Benchtop Laboratory Equipment Operations (15% and 11% of the Company’s total revenues).
  6.
The Company is currently evaluating the effect of this update on its consolidated financial statements.
The Company has not changed its valuation techniques in measuring the fair value of any financial assets and liabilities during the period.
Sales to one and six customers during the six months ended December 31, 2017 and 2016, accounted for approximately 64% and 97% of the Catalyst Research Instrument Operations’ revenues and 4% and 29% of the Company’s total revenues, respectively.
Sales to one and six customers during the six months ended December 31, 2017 and 2016, accounted for approximately 64% and 97% of the Catalyst Research Instrument Operations’ revenues and 4% and 29% of the Company’s total revenues, respectively.
  6.
As of December 31, 2017, estimated future amortization expense related to intangible assets is $124,700 for the remainder of the fiscal year ending June 30, 2018, $185,800 for fiscal 2019, $65,400 for fiscal 2020, $48,000 for fiscal 2021, $27,000 for fiscal 2022, and $7,400 thereafter.
The updated guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years.
The updated guidance is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years.
 Level 2 - Quoted prices in markets that are not considered to be active or financial instruments for which all significant inputs are observable, either directly or indirectly.


item2.txt
In addition, the Company utilized $245,400 of its borrowing availability under the line as collateral for a warranty standby letter of credit required during a two year warranty period as a condition of sale for a large order of catalyst research instruments shipped in a prior fiscal year and installed in the first quarter of fiscal 2018, leaving an available borrowing balance of $14,600 under the line of credit.
  Forward-Looking statements.
  The Company's working capital decreased by $191,500 to $3,782,400 as of December 31, 2017 compared to $3,973,900, as of June 30, 2017 due to increased capital expenditures and a net loss incurred during the current period.
 General and administrative expenses for the three months ended December 31, 2017 amounted to $407,900 compared to $409,200 for the three months ended December 31, 2016.
 As a result of the foregoing, the Company recorded a net loss of $81,000 for the three months ended December 31, 2017 compared to net income $45,300 for the three months ended December 31, 2016.
 Selling expenses for the six months ended December 31, 2017 decreased $25,300 (5.7%) to $415,600 from $440,900 for the six months ended December 31, 2016, due to lower sales related expenses for the Catalyst Research Instruments Operations.
 Overview.
 Selling expenses for the six months ended December 31, 2017 decreased $25,300 (5.7%) to $415,600 from $440,900 for the six months ended December 31, 2016, due to lower sales related expenses for the Catalyst Research Instruments Operations.
  Evaluation of Disclosure Controls and Procedures.
  Changes in Internal Control Over Financial Reporting.
 The Company reflected an income tax expense of $97,400 for the three months ended December 31, 2017 compared to income tax expense of $19,500 for the three months ended December 31, 2016, primarily due to a revision of the estimate of the Company's expected annual income.


item4.txt
 Item 6.


